EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"HealthCap","pharmaFlowCategory":"D","amount":"$26.4 million","upfrontCash":"Undisclosed","newsHeadline":"Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Theragnostics","pharmaFlowCategory":"D","amount":"$44 million","upfrontCash":"$2.5 million","newsHeadline":"Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics Doses First Patient with Its First-in-class Targeted Radiopharmaceutical Drug Satoreotide in Its Phase Ib Study in Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to Test its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Ariceum Therapeutics

    Menu

    Ariceum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ariceum Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblas...

              Details:

              ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.

              Lead Product(s): ATT001

              Therapeutic Area: Oncology Product Name: ATT001

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ariceum Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to Test its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

              Details:

              ATT001 is iodine-123 labelled PARP inhibitor, which is currently being evaluated in preclinical studies for the treatment of patients with recurrent glioblastoma.

              Lead Product(s): ATT001

              Therapeutic Area: Oncology Product Name: ATT001

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ariceum Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics Doses First Patient with Its First-in-class Targeted Radiopharmaceutical Drug Satoreotide in Its Phase Ib Study in Small Cell Lung Cancer

              Details:

              177Lu-OPS201 (satoreotide) is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer.

              Lead Product(s): 68Ga-satoreotide Trizoxetan,177Lu-satoreotide Tetraxetan

              Therapeutic Area: Oncology Product Name: SSO120

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ariceum Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

              Details:

              The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent glioblastoma.

              Lead Product(s): ATD-001

              Therapeutic Area: Oncology Product Name: ATD-001

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Theragnostics

              Deal Size: $44 million Upfront Cash: $2.5 million

              Deal Type: Acquisition June 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ariceum Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

              Details:

              Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undislcosed

              Highest Development Status: Discovery Product Type: Peptide

              Partner/Sponsor/Collaborator: UCB Pharma S.A

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ariceum Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

              Details:

              The proceeds from the financing will enable Ariceum to further develop its lead asset and proprietary peptide derivative, 177Lu-OPS201 (satoreotide). Satoreotide is a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor.

              Lead Product(s): Satoreotide Tetraxetan

              Therapeutic Area: Oncology Product Name: 177Lu-OPS201

              Highest Development Status: Phase I/ Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: HealthCap

              Deal Size: $26.4 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY